Beranda › Kanker Paru Non-Sel Kecil › Virginia › Charlottesville
Uji klinis Kanker Paru Non-Sel Kecil di Charlottesville, VA
21 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Charlottesville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #66, Charlottesville
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Menerima pesertaFase 2
- University of Virginia, Charlottesville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- UVA Comprehensive Cancer Center, Charlottesville
- UVA Health Fontaine Research Park, Charlottesville
- University of Virginia, Charlottesville
- dan 1 lainnya
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Menerima pesertaFase 2
- University of Virginia Cancer Center, Charlottesville
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- University of Virginia Health System, Charlottesville
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Menerima pesertaFase 2/3
- University of Virginia Health System, Charlottesville
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Menerima pesertaFase 3
- Clinical Study Site, Charlottesville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Menerima pesertaFase 3
- University of Virginia Health System, Charlottesville
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Menerima pesertaFase 1/2
- University of Virginia Cancer Center, Charlottesville
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Menerima pesertaFase 3
- Research Site, Charlottesville
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Menerima pesertaFase 3
- University of Virginia, Charlottesville
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
Menerima pesertaFase 2
- UVA Comprehensive Cancer Center, Charlottesville
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- University of Virginia Cancer Center, Charlottesville
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- University of Virginia Cancer Center, Charlottesville
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- University of Virginia Cancer Center, Charlottesville
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Menerima pesertaFase 2
- University of Virginia Health System, Charlottesville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Menerima pesertaFase 1/2
- University of Virginia, Charlottesville
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Menerima pesertaFase 2
- University of Virginia Health System, Charlottesville
GEMINI-NSCLC: NSCLC Biomarker Study
Menerima pesertaStudi observasional
- University of Virginia, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Charlottesville
A Study of NX-1607 in Adults With Advanced Malignancies
Menerima pesertaFase 1
- University of Virginia, Charlottesville
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Studi lain di Charlottesville
- Leukemia Mieloid Akut16 studi
- Kanker Prostat15 studi
- Kanker (semua jenis)13 studi
- Kanker Endometrium13 studi
- Kanker Metastatik13 studi
- Kanker Paru13 studi
- Gagal Jantung12 studi
- Kanker Kolorektal10 studi
- Kanker Ovarium10 studi
- Diabetes Tipe 19 studi
- Kanker Payudara9 studi
- Kanker Pankreas9 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.